Literature DB >> 22705152

Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects.

Angélique Biancotto1, Xingmin Feng, Marc Langweiler, Neal S Young, J Philip McCoy.   

Abstract

INTRODUCTION: Cytokines are humoral regulatory molecules that act together in immunologic pathways. Monitoring cytokines and their variations within physiologic ranges is critical for biomarker discovery. Therefore, we evaluated the performance characteristics of 72 analytes measured by multiplex cytokine immunoassay, with an emphasis on the differences of analytes measured in serum compared to plasma, and, in plasma, on the impact of anticoagulants on the cytokine measurement.
METHODS: We used fluorescent bead-based (Luminex) immunoassay kits to simultaneously measure 72 analytes. We tested serum and plasma samples from 11 matched donors. Plasma samples were anti-coagulated with sodium heparin, sodium citrate dextrose and ethylene diamine tetra-acetic acid (EDTA), respectively.
RESULTS: Of the 72 cytokines, 12 were undetectable in all types of specimen samples. Nineteen analytes, including PDGF-bb, IL-4, IL-8, IL-9, FGF-b, PAI-1, CXCL-5, CCL-5, CD40L, EGF, VEGF, IL-2ra, IL-3, SDF-1a, PCT, MCP-3, GIP, IL-16 and fibrinogen, showed significant differences between measurements in serum and all types of plasma, regardless of anticoagulant. Among plasma samples, 10 analytes (eotaxin, SCGF-b, MCP-1, SCF, MIP-1b, VEGF, RANTES, PDGF-b, PAI-1 and ITAC) showed significantly higher concentrations in heparinized plasma compared to citrated and EDTA plasma. IP-10, and CTAK were the only 2 cytokines that presented different concentrations in citrate and EDTA plasma.
CONCLUSIONS: With their small volume, low cost per test, and multiplex capacity, Luminex-based cytokine assays have enormous potential utility for screening in epidemiologic studies. In our study, we showed that many cytokines' concentrations differed between serum and plasma samples, and that different anticoagulants used in preparation of plasma samples also affected the measurement of some cytokines. There was no optimal sample preparation that was clearly superior for the measurement of all analytes measured. Ultimately, the utility of cytokine measurement, as biomarker or to monitor the immune system, will depend on attention to detail in the collection and processing of samples in addition to assay precision. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22705152      PMCID: PMC3449030          DOI: 10.1016/j.cyto.2012.05.019

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  18 in total

1.  Should soluble CD40 ligand be measured from serum or plasma samples?

Authors:  Dániel Bereczki; Emõke Nagy; András Pál; Mária T Magyar; József Balla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-01       Impact factor: 8.311

2.  Multiplex assays of inflammatory markers, a description of methods and discussion of precautions - Our experience through the last ten years.

Authors:  Kristin Skogstrand
Journal:  Methods       Date:  2011-10-07       Impact factor: 3.608

3.  Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method.

Authors:  Anna Margrét Halldórsdóttir; Joshua Stoker; Rhonda Porche-Sorbet; Charles S Eby
Journal:  Clin Chem       Date:  2005-06       Impact factor: 8.327

4.  Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA.

Authors:  Mohamed F Elshal; J Philip McCoy
Journal:  Methods       Date:  2006-04       Impact factor: 3.608

5.  Solid-phase and bead-based cytokine immunoassay: a comparison.

Authors:  Wilco de Jager; Ger T Rijkers
Journal:  Methods       Date:  2006-04       Impact factor: 3.608

6.  Influence of sample type and storage conditions on soluble CD40 ligand assessment.

Authors:  Michael Weber; Birgitt Rabenau; Michael Stanisch; Albrecht Elsaesser; Vesselin Mitrovic; Christopher Heeschen; Christian Hamm
Journal:  Clin Chem       Date:  2006-03-09       Impact factor: 8.327

Review 7.  Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids.

Authors:  R F Grimble; P S Tappia
Journal:  Z Ernahrungswiss       Date:  1998

8.  Tumor necrosis factor measurement and use of different anticoagulants: possible interference in plasma samples and supernatants from endotoxin-stimulated monocytes.

Authors:  J N Hoffmann; W H Hartl; E Faist; M Jochum; D Inthorn
Journal:  Inflamm Res       Date:  1997-09       Impact factor: 4.575

9.  Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum.

Authors:  Chad A Ray; Ronald R Bowsher; Wendell C Smith; Viswanath Devanarayan; Mark B Willey; John T Brandt; Robert A Dean
Journal:  J Pharm Biomed Anal       Date:  2005-01-04       Impact factor: 3.935

10.  Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions.

Authors:  P W Thavasu; S Longhurst; S P Joel; M L Slevin; F R Balkwill
Journal:  J Immunol Methods       Date:  1992-08-30       Impact factor: 2.303

View more
  37 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

2.  Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Authors:  Shernan G Holtan; Michael R Verneris; Kirk R Schultz; Laura F Newell; Gabrielle Meyers; Fiona He; Todd E DeFor; Gregory M Vercellotti; Arne Slungaard; Margaret L MacMillan; Sarah A Cooley; Bruce R Blazar; Angela Panoskaltsis-Mortari; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-07       Impact factor: 5.742

Review 3.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

4.  Aptamer-based proteomics of serum and plasma in acquired aplastic anemia.

Authors:  Valentina Giudice; Angélique Biancotto; Zhijie Wu; Foo Cheung; Julián Candia; Giovanna Fantoni; Sachiko Kajigaya; Olga Rios; Danielle Townsley; Xingmin Feng; Neal S Young
Journal:  Exp Hematol       Date:  2018-10-09       Impact factor: 3.084

Review 5.  Considerations for Soluble Protein Biomarker Blood Sample Matrix Selection.

Authors:  Joel A Mathews; Yan G Ni; Connie Wang; Jon E Peterson; Chad Ray; Xuemei Zhao; Daoyu Duan; Sara Hamon; John Allinson; Martha Hokom; Greta Wegner
Journal:  AAPS J       Date:  2020-01-29       Impact factor: 4.009

6.  Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients.

Authors:  Larry A Harshyne; Brian J Nasca; Lawrence C Kenyon; David W Andrews; D Craig Hooper
Journal:  Neuro Oncol       Date:  2015-07-14       Impact factor: 12.300

7.  Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop.

Authors:  Danielle M Carrick; Anil K Chaturvedi; Meredith S Shiels; Rao L Divi; Kelly K Filipski; Elizabeth F Hebert; Mukesh Verma; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-24       Impact factor: 4.254

8.  Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.

Authors:  Eric S Weiss; Charlotte Girard-Guyonvarc'h; Dirk Holzinger; Adriana A de Jesus; Zeshan Tariq; Jennifer Picarsic; Eduardo J Schiffrin; Dirk Foell; Alexei A Grom; Sandra Ammann; Stephan Ehl; Tomoaki Hoshino; Raphaela Goldbach-Mansky; Cem Gabay; Scott W Canna
Journal:  Blood       Date:  2018-01-11       Impact factor: 22.113

9.  Inverse association between maternal 25OHD level and cord GLP-1/GIP concentrations.

Authors:  Shimpei Niwa; Hidetoshi Mezawa; Naoaki Kobayashi; Hiroyuki Ida; Mitsuyoshi Urashima
Journal:  Pediatr Res       Date:  2015-12-09       Impact factor: 3.756

10.  Location, location, location: cytokine concentrations are dependent on blood sampling site.

Authors:  Juan Rodolfo Mella; Evan L Chiswick; Elizabeth King; Daniel G Remick
Journal:  Shock       Date:  2014-10       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.